Search results
Results from the WOW.Com Content Network
The NASDAQ Biotechnology Index is a stock market index made up of securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either the Biotechnology or the Pharmaceutical industry. [1] A list of the 225 components of the index is published online.
The price of an existing patented drug cannot increase by more than the Consumer Price Index (CPI) The price of a new drug (in most cases) is limited so that the cost of therapy with the new drug is in the range of the costs of therapy with existing drugs in the same therapeutic class. The price of a breakthrough drug is limited to the median ...
Rank Brand Name(s) Generic Name Sales Q1 2014 Sales ($000) Change from Q4 2013 Company(ies) Disease/Medical Use First Approval Date Patent Expiration Date [6] [7]; 1: Abilify
The most commonly known index fund in the United States, the S&P 500 Index Fund, is based on the rules established by S&P Dow Jones Indices for their S&P 500 Index. Equity index funds would include groups of stocks with similar characteristics such as the size, value, profitability and/or geographic location of the companies.
The price paid by pharmacists and doctors is determined mainly by the number of license holders, the sales value of the original brand, and the ease of manufacture. A typical price decay graph will show a "scalloped" curve, [25] which usually starts at the brand-name price on the day of generic launch and then falls as competition intensifies ...
In 2020, the US DOJ fined Apotex $24,100,000 for colluding with other pharmaceutical companies to price fix—raising costs of vital drugs for users who needed its cholesterol medicine. In the words of Special Agent in Charge Scott Pierce: "When generic drug companies conspire to fix prices and rig bids, they do so to the detriment of many who ...
The Access to Medicine Index covers a range of diseases based on their aggregate global disease burden and their relevance to pharmaceutical interventions, in accordance with non-age-weighted WHO Disability Adjusted Life Years (DALY) [21] data. In the 2024 Index, the disease scope included 81 diseases, conditions and pathogens identified as the ...
The rate of decay of most generic solid dose products has been shown to follow a predictable path and to have some similarity to the decay in price of other non pharmaceutical products. [21] [22] Eventually price decline comes to and end and the price flattens out at approximately 20% of the original brand price.